



Contact
Troy Kehoe
JavaCulture Agency
630-803-4436
troy@javacultureagency.com

For Immediate Release

Long Grove Pharmaceuticals Launches First and Only Single-Pack Presentation for Carboprost Tromethamine Injection, USP

Emerging Generics Leader Continues to Provide Innovative Solutions with Latest FDA-Approved Generic

ROSEMONT, Ill. – [Long Grove Pharmaceuticals®](#), founded in 2019 by strategic health care investor Water Street Healthcare Partners, today announced the launch of the first and only commercially available single-pack for its latest generic to market, Carboprost Tromethamine Injection, USP.

Long Grove Pharmaceuticals' Carboprost Tromethamine Injection, USP is AP Rated and is therapeutically equivalent to Pfizer's Hemabate®. Carboprost Tromethamine Injection, USP is TAA Compliant and made in Canada.

"We are thrilled to offer the first single-pack presentation of Carboprost Tromethamine to continue to provide flexibility to hospitals, pharmacy departments, and patients," said Dan Robins, Ph.D., President & CEO of Long Grove Pharmaceuticals. "Utilizing our team's extensive experience in supply chain management and commercial insight, we remain focused on bringing even more flexibility to the market through product presentations like this."

Long Grove Pharmaceuticals' Carboprost Tromethamine Injection, USP marked the second product launch for the company in 2022 as it continues to emerge as a new U.S. generic pharmaceuticals leader. The company focuses on complex generics, including injectables and topical products, and is committed to improving customer choice while increasing access for patients.

For more information about Carboprost Tromethamine Injection, USP, including the boxed warning for dosing and administration guidance, please visit longgrovepharma.com/carboprost-tromethamine.

CARBOPROST TROMETHAMINE INJECTION, USP Important Safety Information

WARNINGS

Carboprost tromethamine injection sterile solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Carboprost tromethamine injection should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.

About Long Grove Pharmaceuticals®

Long Grove Pharmaceuticals was established in 2019 by Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The company is part of Capstone Development Services, which has been developing products in partnership with the world's premier pharmaceutical and medical device organizations since 2013. Combining decades of collective leadership experience with a portfolio of specialized, complex generic drug formulations, Long Grove Pharmaceuticals is poised to innovate across the generic injectable and topical markets.